Background: Immune checkpoint inhibitors (ICI) have emerged as a successful treatment
option for diverse cancer entities. However, ICI therapy can be associated with immune …

Background: Immune checkpoint inhibitors (ICI) have emerged as a successful treatment
option for diverse cancer entities. However, ICI therapy can be associated with immune …

Background Checkpoint immunotherapy is a rapidly evolving treatment paradigm for solid
organ cancers. 1 These medications are often antibodies that target key regulators of the …

Purpose This study investigated the experience of palliative care physicians (PCPs) and
their knowledge and recognition of immune checkpoint inhibitors (ICIs) and immune-related …

A 49‐year‐old man diagnosed with metastatic non‐small cell lung cancer was treated with
immune checkpoint inhibitor (ICI) combination therapy (nivolumab+ ipilimumab) as first‐line …

Immune checkpoint inhibitors (ICIs) have opened an exciting chapter in the treatment of
patients with advanced cancer. For the palliative care clinician, however, ICIs present …

Introduction Immune agents including anti-programmed death receptor-1 and anti-cytotoxic
T-lymphocyte antigen-4 have been associated with numerous immune-related …

Background: Immunotherapy (IO) is known to improve survival and outcome in various types
of solid tumours. However, nonspecific activation of the immune system also affects various …

3096 Background: Disruption of the immune system using immune checkpoint inhibitors can
result in a multitude of immune-related adverse effects (irAE). While irAEs have been well …

Immune-related adverse events (irAEs) are toxicities resulting from use of immune
checkpoint inhibitors (ICIs). These side effects persist in some patients despite withholding …